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 The goal of this study was to determine the best predictive factor among 
image-derived parameters extracted from sequential 18F-FDG Positron Emission 
Tomography (PET) scans for early tumor response prediction after two cycles of 
neoadjuvant chemotherapy (NAC) in breast cancer. 
 Methods: 51 breast cancer patients were included. Responders and non-
responders status were determined in histopathology according to the tumor and 
nodes Sataloff scale. PET indices (SUVmax and SUVmean, metabolically active tumor 
volume and total lesion glycolysis (TLG)), at baseline and their evolution (Δ) after two 
cycles of NAC were extracted from the PET images. Their predictive value was 
investigated using Mann-Whitney-U tests and ROC analysis. Sub-group analysis was 
also carried out by considering ER-positive/HER2-negative, triple-negative, and 
HER2-positive tumors separately. The impact of partial volume correction (PVC) was 
also investigated using an iterative deconvolution algorithm. 
 Results: There were 24 pathological non-responders and 27 responders. None 
of the baseline PET parameters was correlated with response. After two NAC cycles, 
the reduction of each parameter was significantly associated with response, the best 
prediction of response being obtained with ΔTLG (96% sensitivity, 92% specificity, 
94% accuracy) with significantly higher AUC (0.91 vs. 0.82, p=0.01) than ΔSUVmax 
(63% sensitivity, 92% specificity, 77% accuracy). Sub-group analysis confirmed a 
significantly higher accuracy for ΔTLG than ΔSUV for ER-positive/HER-negative, but 
not for triple-negative and HER2-positive tumors. PVC had no impact on the 
predictive value of any of the PET image derived parameters despite significant 
changes of their absolute values. 
 3 
 Conclusion: Our results suggest that the reduction after two NAC cycles of the 
metabolically active volume of primary tumor measurements such as ΔTLG predicts 
histopathological tumor response with higher accuracy than ΔSUV measurements, 
especially for ER-positive/HER2-negative breast cancer. These results should be 
confirmed in a larger group of patients as they may potentially increase the clinical 
value and efficiency of 18F-FDG PET for early prediction of response to NAC. 
 
Keywords: Breast cancer, Neoadjuvant chemotherapy, 18F-FDG, tumor 
delineation, pathological response 
 4 
Introduction 1 
Preoperative neoadjuvant chemotherapy (NAC) has been used as standard 2 
treatment for inflammatory and non-operable locally advanced breast carcinoma 3 
patients and it is now increasingly being used for patients with operable but large 4 
breast tumors. This strategy allows patients to undergo breast-conserving surgery 5 
(BCS) and provides information regarding the efficacy of chemotherapy (1). Early 6 
response prediction after one or two cycles of NAC might enable the selection of 7 
alternative treatment strategies (2). Breast carcinoma is composite and 8 
immunohistochemistry allows defining three main subgroups with different 9 
therapeutic response and different outcome (triple negative, HER2+ and luminal 10 
tumors). Pathological Complete Response (pCR) is associated with a better outcome 11 
in the HER2-overexpressed and triple negative breast cancer patients. On the other 12 
hand, recent studies showed than in luminal tumors, especially for luminal A, the 13 
impact of pCR on patient’s survival remains less established (3, 4). Thus an 14 
intermediate response with tumor shrinkage allowing BCS might be considered as a 15 
reasonable clinical objective for this group. 16 
Within this context, 18F-FDG PET imaging has been demonstrated as a potent 17 
predictive tool (5-8). Indeed, correlations between the pathological tumor response 18 
after completion of NAC and the decrease of tumor standardized uptake values 19 
(SUV) after one or two courses of chemotherapy have been demonstrated in several 20 
studies. A recent meta-analysis (8) conducted on 19 studies including 920 patients 21 
for the early prediction of primary tumor response to NAC reported a pooled 22 
sensitivity of 84% and specificity of 66% in identifying responders. The authors 23 
emphasized that the low pooled specificity (66%) still calls for caution.  24 
 5 
Most studies have considered SUV measurements only; mostly SUVmax, or SUVpeak 1 
averaging the SUVmax voxel with its neighboring voxels (9). On the other hand, it has 2 
been demonstrated in several recent studies and for various malignancies that other 3 
18F-FDG PET image derived parameters can have statistically significant higher 4 
predictive value than SUV in determining tumor response (10, 11). These 5 
parameters, which allow for a more comprehensive tumor functional level evaluation, 6 
include metabolically active tumor volume (MATV) (11) and total lesion glycolysis 7 
(TLG), defined as the product of MATV and its associated mean SUV (SUVmean) (12). 8 
One recent study compared SUVmax and TLG derived using manual delineation and 9 
threshold, showing that SUVmax had better predictive value than TLG in identifying 10 
pCR (13). 11 
To the best of our knowledge, no study has investigated the predictive value, 12 
regarding response to NAC for breast cancer, for all of the previously described 18F-13 
FDG PET image derived parameters (SUVmax, SUVmean, SUVpeak, TLG, MATV) within 14 
the same study, at both the baseline and during treatment time points. 15 
The current study was therefore conducted with the objective of determining the 16 
predictive value of several 18F-FDG PET derived parameters both at baseline and 17 
after two NAC cycles. 18 
 19 
MATERIALS AND METHODS 20 
Patient Population 21 
The current study consists of a retrospective analysis of a prospective cohort of 55 22 
consecutive patients diagnosed with breast cancer included in a previous clinical trial 23 
(14), performed in agreement with guidelines of the institutional ethical committee 24 
with patients’ informed consent. PET/CT image datasets of 3 patients could not be 25 
 6 
retrieved from the database due to a corrupt archive file, and one was excluded from 1 
the analysis due to insufficient initial uptake (SUVmax=1.5) in the primary tumor. 2 
Therefore 51 patients were included in the retrospective analysis presented in this 3 
work (table 1). 4 
All patients underwent NAC with four cycles of epirubicin + cyclophosphamide, 5 
followed by four cycles of docetaxel (+Herceptin in case of HER2+++). Patients 6 
underwent 18F-FDG PET/CT scans at baseline and after the second cycle of NAC. 7 
From here onwards, these scans will be denoted as PET1 and PET2 respectively. At 8 
completion of chemotherapy, all patients underwent surgery (mastectomy or 9 
lumpectomy). 10 
 11 
18F-FDG PET/CT acquisitions 12 
All 18F-FDG PET/CT scans were performed at Saint Louis Hospital in Paris between 13 
July 2007 and May 2009. A rigorous imaging protocol was designed to ensure robust 14 
SUV measurements across both time points. Blood glucose level had to be ≤7 15 
mmol/L. For both acquisitions, patients received an intravenous injection (in the arm 16 
opposite to the breast tumor using a venous line) of 18F-FDG (5 MBq/kg) after a 17 
fasting period of 6 hours. Following an uptake period of 60 minutes, all acquisitions 18 
were carried out from mid-thigh level to the base of the skull with the arms raised, on 19 
a Philips Gemini Xl PET/CT that combines a germanium oxyorthosilicate–based PET 20 
scanner and a 16-slice Brilliance CT scanner. CT data were acquired first (120 kV, 21 
100 mAs, no contrast enhancement). PET emission list mode data were acquired in 22 
3D mode, with 2 min per bed position, and reconstructed using a 3D row-action 23 
maximum-likelihood (RAMLA) algorithm with voxel size of 4×4×4mm3. The 24 
 7 
attenuation corrected images were normalized for injected dose and body weight and 1 
converted into standardized uptake values (SUVs) defined as: 2 
tracer concentration [kBq/mL] / (injected activity [kBq] / patient body weight [g]) 3 
 4 
Tumor Histology and Immunohistochemistry Analysis 5 
Tumor type was determined on the core needle biopsy performed before 6 
neoadjuvant chemotherapy. Immunohistochemical tests were performed on formalin-7 
fixed, paraffin embedded tissues, using specific antibodies and an automated 8 
immunostainer (XT Immunostainer; Ventana). Tumors were considered to 9 
overexpress HER2 (HER2+++) if more than 30% of invasive tumor cells showed 10 
definite membrane staining resulting in a so-called fishnet appearance; control by 11 
FISH (fluorescence in situ hybridization) or SISH (silver enhanced in situ 12 
hybridization) was done for ambiguous cases. Tumors were considered estrogen 13 
receptor (ER)–negative or progesterone receptor (PR)–negative if there was less 14 
than 10% staining. 15 
Three specific tumor subgroups as described previously were considered, namely 16 
triple-negative, ER-positive/HER2-negative (luminal) and HER2-positive. 17 
 18 
Pathological Tumor Response  19 
Histopathological response was assessed on surgical specimens at completion of 20 
NAC. Response was graded according to the Sataloff scale in primary tumor (T) and 21 
nodes (N) (15), that was used in the frequently cited study by Rousseau et al (6) : 22 
TA: total or nearly-total therapeutic effect, TB: >50% therapeutic effect but less than 23 
total or nearly-total effect, TC: <50% therapeutic effect but visible effect, TD: no 24 
therapeutic effect, NA: evidence of therapeutic effect and no residual disease, NB: no 25 
 8 
node metastases or therapeutic effect, NC: evidence of a therapeutic effect but 1 
metastasis still present, ND: metastasis still present and viable, no therapeutic effect. 2 
Complete and partial responders [T(A-B) with N(A-B-C)] were considered as 3 
histopathological responders, whereas patients with no response or progression 4 
[T(C-D), N(D)] were considered as non-responders.  5 
The pCR rate, defined as absence of invasive cancer cells in the primary tumor and 6 
in lymph nodes (16) was also evaluated and the predictive power of PET parameters 7 
to predict pCR was measured. 8 
 9 
Investigated Parameters and Analysis 10 
All PET image-derived parameters were extracted from the PET1 and PET2 images. 11 
For each patient, the primary tumor was identified on the PET image by a nuclear 12 
medicine physician with more than 10 years experience and subsequently semi-13 
automatically isolated in a 3D region of interest (ROI) containing the tumor and its 14 
surrounding background. Tumors were subsequently automatically delineated using 15 
the Fuzzy Locally Adaptive Bayesian (FLAB) algorithm (17) applied to the previously 16 
defined ROI. The FLAB approach allows automatic tumor delineation by computing a 17 
probability of belonging to a given “class” (e.g. tumor or background) for each voxel 18 
within the 3D ROI. This probability is calculated by taking into account the voxel’s 19 
intensity with respect to the statistical distributions (characterized by their mean and 20 
variance) of the voxels in the various regions of the image, as well as its spatial 21 
correlation with neighboring voxels in 3D. This approach has been previously 22 
validated on simulated and clinical datasets for accuracy, robustness and 23 
reproducibility, on both homogeneous and heterogeneous MATVs (17-19).  24 
 9 
Potential impact of partial volume effects (PVE) was also investigated by correcting 1 
the image before analysis using a state-of-the-art iterative deconvolution previously 2 
validated for oncology PET imaging applications (20). The analysis was subsequently 3 
carried out on both the original and PVE corrected (PVC) images. 4 
SUVmax, SUVpeak and SUVmean as well as the MATV and the TLG were then 5 
automatically calculated from the tumor delineations. SUVpeak was defined as the 6 
mean of voxels intensities in a 1.7 cm3 spheric ROI (27 voxels) centered on SUVmax 7 
(9). MATV was defined as the sum of all voxels contained in the FLAB delineated 8 
volumes multiplied by the volume of a voxel (64 mm3). SUVmean was defined as the 9 
mean of voxel intensities in the MATV delineated by FLAB. Subsequently, TLG was 10 
determined by multiplying the MATV and its associated SUVmean. The percentage 11 
evolution of each parameter between baseline and after the second NAC cycle 12 
(Δparam, %) was calculated as : 13 
Δparam = (param_PET2 – param_PET1) / param_PET1 × 100. 14 
 15 
Statistical Analysis 16 
Statistical analyses were performed using MedCalcTM (MedCalc Software, Belgium). 17 
All parameters’ distributions were expressed as median (or mean depending on 18 
normality) ± standard deviations (SD) and range (minimum, maximum). Normality 19 
was tested using D'Agostino-Pearson test (21). For each parameter, its correlation 20 
with patient response was carried out by testing the statistical difference between 21 
responders’ and non-responders’ distributions using a Mann-Whitney U test. For 22 
each parameter, their absolute values at PET1 and PET2, as well as their evolution 23 
Δ(PET1, PET2) were investigated. The predictive performance regarding the 24 
identification of responders was evaluated using receiver operating characteristic 25 
 10 
(ROC) analysis. Area under the curve (AUC), sensitivity, specificity, and accuracy 1 
were reported. Absolute and associated predictive parameters values extracted from 2 
the PVC PET images were compared to original ones. Sub-group analysis was also 3 
carried out by considering triple-negative, HER2-positive, and ER-positive/HER2-4 
negative tumors separately. All tests were two-sided and p values ≤0.05 were 5 
considered statistically significant. 6 
RESULTS 7 
ER, PR and HER2 receptors status are provided in table 1. 13 patients had triple 8 
negative tumors, 12 had HER2-positive tumors, and 26 had ER-positive/HER2-9 
negative tumors, which is representative (22). Considering the pathological tumor 10 
response established at surgery (after completion of chemotherapy), there were 27 11 
pathological responders (53%) and 24 non-responders (47%). pCR was found in 7 12 
patients (13.7%), among which, 3 had triple negative, and 4 had HER2-13 
overexpressing tumors, and 0 were ER-positive/HER2-negative. Figure 1 illustrates 14 
for a pathological non-responder and a responder the two scans, including the 15 
delineation of the primary tumor. 16 
 17 
Predictive Value of Parameters’ Absolute Values 18 
According to the D'Agostino-Pearson test, considering the entire patient cohort 19 
(n=51), none of the parameters’ absolute values at baseline and after the second 20 
cycle or associated variation (Δ) were normally distributed (table 2). Similarly, the 21 
distribution of responders and non-responders groups were not normally distributed 22 
(figure 2), except for the variation (Δ) values (figure 3). 23 
According to Mann-Whitney-U tests, no significant correlation (p>0.1) was observed 24 
between the baseline values and histopathological response (table 2), distributions of 25 
 11 
the parameters among responders and non-responders being largely overlapped 1 
(figure 2A), leading to low AUC of 0.52-0.63 (table 3). 2 
Primary tumors of non-responders were characterized by higher PET2 SUVmax 3 
(5.3±6.2 vs. 2.8±2.9, p=0.04) and TLG (30±160 vs. 14±13, p=0.05). However, no 4 
correlation (p≥0.07) was found for all of the other parameters considered (table 2). 5 
For all parameters, the distributions were largely overlapped (figure 2A-C), as the 6 
results of ROC analysis demonstrate, with low AUC of 0.62-0.67 (table 3). For SUV, 7 
sensitivity (57-69%) and specificity (71-75%) were limited. On the other hand, for 8 
volume-based measurements, sensitivity was higher (89% and 78% for MATV and 9 
TLG respectively) but specificity was lower (42% and 63% for MATV and TLG 10 
respectively).  11 
 12 
Evolution of Parameters and Associated Predictive Value 13 
There was a global trend of decreasing MATV and associated tumors’ uptake after 14 
the first two NAC cycles, although for some patients PET image derived parameters 15 
were also found to be increasing (table 2). The lowest and largest decrease were 16 
observed for ΔSUVmax (-34%±32%) and ΔTLG (-59%±34%) respectively. 17 
According to Mann-Whitney-U tests, the variation (Δ) of all parameters was 18 
statistically different between responders and non-responders, especially for ΔMATV 19 
and ΔTLG (p<0.0001), as well as ΔSUVmax (p=0.0001) (table 2). 20 
According to ROC analysis, the best prediction was achieved using the ΔTLG, with a 21 
sensitivity of 96% and specificity of 92% resulting in an accuracy of 94% (table 3). 22 
The ΔMATV was also an accurate predictive factor (sensitivity 93%, specificity 88%, 23 
accuracy 91%). On the other hand, ΔSUV measurements led to significantly lower 24 
AUCs (0.68 for ΔSUVmean to 0.82 for ΔSUVmax vs. 0.91 and 0.92 for ΔMATV and 25 
 12 
ΔTLG, p≤0.01) (figure 4A), with significantly lower sensitivity (63-74%), specificity 1 
(67-92%) and resulting accuracy (71-77%) (table 3). The least overlapped 2 
distributions were those associated with ΔMATV and ΔTLG (figure 3). The optimal 3 
cut-off values maximizing sensitivity and specificity were -48%, -42%, -30%, -42% 4 
and -56% for ΔSUVmax, ΔSUVpeak, ΔSUVmean, ΔMATV and ΔTLG respectively (table 5 
3, figure 3). 6 
 7 
Tumor Subgroup Analysis 8 
When considering ER-positive/HER2-negative patients (n=26), all AUCs were slightly 9 
higher but with the same hierarchy as for the entire cohort: ΔTLG and ΔMATV 10 
resulted in AUC of 0.96 and 0.98 respectively, whereas ΔSUV measurements led to 11 
AUC of 0.69, 0.84 and 0.88 for ΔSUVmean, ΔSUVpeak and ΔSUVmax respectively. 12 
The ROC analysis performed on the 12 HER2-positive and 13 triple-negative patients 13 
resulted in non-statistically significant different AUCs for volume-based and SUVs 14 
(p>0.05) in both cases. 15 
 16 
Prediction of pCR 17 
The pCR predictive value of all parameters was reduced with respect of the 18 
prediction of partial response. The hierarchy was however similar with AUCs of 0.76, 19 
0.79, 0.67, 0.63 and 0.59 for ΔTLG, ΔMATV, ΔSUVmax, ΔSUVpeak, and ΔSUVmean 20 
respectively (figure 5A). 21 
 22 
Impact of Partial Volume Effects Correction 23 
The correction of partial volume effects had no significant impact on the resulting 24 
variation (Δ) of neither SUV nor volume-based parameters, despite the significant 25 
 13 
impact on their PET1 and PET2 absolute values. There were therefore no statistically 1 
significant differences between the AUCs of ROC curves generated using Δ(%) 2 
calculated using the original and PVC PET image derived parameters (figure 4B, 5B).  3 
 4 
DISCUSSION 5 
The current study is the first investigation into the predictive value of 18F-FDG 6 
PET derived parameters on a breast cancer cohort, including baseline three different 7 
SUV measurements, MATV and TLG and their evolution (Δ). Our results are in 8 
contradiction with the ones of the only other study to date comparing the 9 
performance of ΔSUVmax and ΔTLG, that reported a higher predictive value for 10 
ΔSUVmax (13). In this study, ΔSUVmean, ΔSUVpeak or ΔMATV predictive values were 11 
not considered. In addition, ΔTLG values were derived from tumor volumes 12 
delineated through manual contouring using a fixed threshold. Such a delineation 13 
approach has been previously shown to be inaccurate for PET imaging (23, 24). In 14 
our study a previously validated robust and reproducible MATV segmentation 15 
algorithm was used. Another difference is that results in the previously reported study 16 
were reported for the prediction of pCR only, corresponding to 17% of the 142 17 
patients, with a resulting cut-off ΔSUVmax value of 83-88%, which led to high 18 
specificity (96%) but low sensitivity (67%). In our study, we considered as 19 
pathological responders patients with complete or partial response in the primary 20 
breast cancer and lymph nodes. According to this criterion we found that MATV and 21 
TLG were more predictive than SUV. We refined a subsequent analysis considering 22 
pCR only for responders and we observed also than volume parameters were 23 
superior (AUC 0.76-0.79) to SUV (0.59-0.67). 24 
 14 
In contrast to results in several malignancies such as locally advanced 1 
esophageal cancer (11) or non-Hodgkin lymphoma (10), none of the absolute 2 
baseline values (with or without PVC) was significantly associated with response. 3 
The absolute values of some parameters (SUVmax and TLG) after the second cycle 4 
(PET2) were significantly correlated with response but had limited predictive value. 5 
The most powerful predictive factors were the evolution between the baseline and 6 
the second scan (Δ).  7 
 8 
Pathological responders were associated with a significantly higher decrease 9 
of the 18F-FDG PET derived indices considered. Among these, the ΔTLG and 10 
ΔMATV were the best predictive factors compared to ΔSUV measurements, with 11 
significantly higher accuracy (91% and 94% for MATV and TLG vs. 71%, 76% and 12 
77% for ΔSUVmean, ΔSUVpeak and ΔSUVmax respectively). With respect to the recent 13 
meta-analysis that reported an overall 84% sensitivity and 66% specificity based on 14 
ΔSUVmax (8), our ΔSUVmax results demonstrated lower sensitivity (63%) but higher 15 
specificity (92%), whereas ΔTLG resulted in both higher sensitivity (96%) and 16 
specificity (92%). The meta-analysis also demonstrated large differences in 17 
sensitivities and specificities among the various considered studies due to 18 
combinations of different patient populations, response criteria (pCR and/or partial 19 
response) and cut-off values. Our study is in line with previous findings that the 20 
reduction (Δ) of PET indices after two cycles are good predictors of response to NAC 21 
in breast cancer (8). We further demonstrated the added value of considering more 22 
complete tumor characterization in 18F-FDG PET images through the delineation of 23 
the MATV over SUV measurements only. On the one hand, these results were 24 
mostly unchanged when performing the analysis on the subgroup of ER+/HER2- 25 
 15 
patients. On the other hand, the respective predictive values of ΔSUV, ΔMATV and 1 
ΔTLG parameters were similar for the triple-negative and HER2-positive patients. 2 
However, since this subgroup analysis included a small number of patients (13 triple-3 
negative and 12 HER2-positive), it needs to be further validated in a larger patient 4 
population. Future validation studies on larger groups of patients will be focused on 5 
ER-positive/HER2-negative patients since it is for this sub-group that the added value 6 
of ΔMATV and ΔTLG over ΔSUV seems to be the most significant. This can be 7 
explained by the fact that ER-positive/HER2-negative tumors are known to exhibit 8 
lower initial FDG uptake and have therefore lower decrease margins (7, 25, 26). 9 
These tumors are also known to only partially respond to NAC, requiring finer 10 
characterization of their response (27, 28). Therefore, the addition of functional tumor 11 
volume-based metrics logically provides improved predictive accuracy for these 12 
tumors. For triple-negative and HER2-positive tumors that exhibit higher FDG uptake 13 
and associated decrease margins, as well as better pCR rates, the addition of 14 
volume-based metrics might not translate into significantly improved predictive value 15 
over ΔSUV measurements. 16 
 17 
Another interesting result of our study was that ΔSUVmean had significantly 18 
lower predictive value than ΔSUVpeak and ΔSUVmax (AUC of 0.68 vs. 0.79 and 0.82, 19 
p<0.02). Considering the use of ΔSUVpeak relative to ΔSUVmax, as proposed by the 20 
PERCIST recommendations (9), in this study there were no statistically significant 21 
differences between the two (AUC 0.82 vs. 0.79, p=0.2), despite ΔSUVmax leading to 22 
slightly better results than ΔSUVpeak. Both these parameters describe the highest 23 
activity region of the tumor, whereas the mean value is a better representative 24 
measurement of the entire tumor. A potential explanation for the lower predictive 25 
 16 
value of ΔSUVmean is its higher dependency on partial volume effects compared to 1 
SUVmax and SUVpeak. It has however been recently shown in a group of 15 breast 2 
cancer patients that PVC had limited impact on the SUV reduction (29), without 3 
reporting however on the actual impact of this reduction on the overall response 4 
predictive value. Another study investigated the impact of PVC on the prediction of 5 
response to NAC for breast cancer using dynamic 18F-FDG PET. They found that 6 
PVC eliminated significant differences in % FDG uptake measurement changes for 7 
non-responders (NR) versus partial responders (PR), but not for pCR versus other 8 
response categories (30). In the aforementioned work PVC was performed using 9 
simplistic recovery coefficients, applied only to tumors with size <3cm based on MR 10 
imaging. In our study, PVC was systematically applied to all images using a 11 
voxelwise iterative image deconvolution algorithm previously validated for PET 12 
images (20). In this work, the use of PVC did not change either the predictive value 13 
of the parameters or their evolution (Δ) or the statistical differences between groups 14 
of response, despite a significant change of their absolute values. Finally, PVC did 15 
not improve the predictive value of SUVmean or the hierarchy of performance between 16 
the three different SUV measurements, for neither the partial or pCR response 17 
criteria. This lack of PVC impact is consistent with our previous findings (31, 32). 18 
 19 
The delineation of breast cancer MATVs is challenging as they often exhibit 20 
heterogeneous uptake distributions and complex shapes and/or low tumor-to-21 
background ratios, particularly in the mid-treatment scan. Therefore the use of a 22 
robust algorithm is recommended. Within this context, the results presented here 23 
using FLAB may be replicated using alternative approaches, such as gradient-based 24 
(33) or improved fuzzy C-means (34) methods. Using less robust approaches might 25 
 17 
lead to significant differences in the results concerning the value of volume derived 1 
parameters (11, 13). In addition, this effect may be more important when considering 2 
the temporal evolution of such parameters, as measurements have to be considered 3 
with respect to the known physiological reproducibility ranges. Difference values 4 
have to be larger than ±30% to characterize response, because of the upper and 5 
lower physiological reproducibility limits associated with PET derived measurements 6 
(19). Considering MATV and TLG values, these reproducibility limits were obtained 7 
using the FLAB method, whereas less robust approaches (fixed and adaptive 8 
threshold) lead to larger values (±50-90%) (19). The FLAB method also allows for 9 
more repeatable measurements, with low inter- and intra-observer variability (18, 19). 10 
Finally, the imaging protocol in this study was specifically designed to ensure robust 11 
and reproducible tumor characterization between both time points. For most patients, 12 
measured evolutions were outside the reproducibility limits. Optimal cut-off values 13 
were also larger; -48% for SUVmax, which is in accordance to previous findings (8), -14 
42% and -56% for MATV and TLG respectively. 15 
 16 
One potential limitation of this study is its retrospective nature and the 17 
resulting potential bias, and the lack of reliable outcome information due to the short 18 
delay between surgery and last follow-up. Another limitation is the relatively small 19 
number of patients due to the previous prospective study that was limited to 55 20 
patients (14), 4 of which could not be exploited in the present study. This small 21 
sample is especially restrictive regarding the subgroup analyses of triple negative 22 
and HER2-positive patients. The findings of this study need therefore to be validated 23 
in larger patient cohorts. Another limitation is that although nodal status was 24 
considered to define pathological response, only primary tumors were characterized 25 
 18 
in the images to simplify the analysis. Finally, some of the patients were 1 
characterized by ΔTLG and ΔMATV decreases that were close to the optimal cut-off 2 
values but sufficient to avoid misclassification, whereas it was the opposite for 3 
SUVmax (figures 3). The statistical difference between AUCs of ΔSUVmax and ΔTLG 4 
might therefore be lower in larger prospective studies. However, it has to be 5 
emphasized that values of ΔMATV and ΔTLG present a higher spread than ΔSUV 6 
measurements as demonstrated in figure 3, showing their higher discriminative 7 
power demonstrated by Mann-Whitney-U tests (table 2).  8 
CONCLUSION 9 
The reduction of metabolically active primary tumor volumes and associated activity 10 
measurements such as Total Lesion Glycolysis after two neo-adjuvant chemotherapy 11 
cycles predicts histopathological tumor response with statistically significant higher 12 
accuracy (94%) than SUVmax (77%). The advantage of TLG over SUVmax was 13 
particularly evident for the 26 patients in the ER-positive/HER2-negative sub-group 14 
and therefore we will focus on confirming these results in a larger group of ER-15 
positive/HER2-negative patients as they may potentially increase the clinical value 16 
and efficiency of 18F-FDG PET for early prediction of response to NAC. 17 
 19 
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Figure 1: Illustration of PET1 (left) and PET2 (right) for (A) a responder (ΔSUVmax -
46%, ΔTLG -89%) and (B) a non-responder (both ΔSUVmax and ΔTLG -43%). The 
green contours represent the FLAB delineation. 
Figure 2: Box-and-whisker distributions plots of (A) SUVmax, SUVpeak, SUVmean, (B) 
MATV and (C) TLG absolute values at PET1 and PET2. One patient with extremely 
high MATV and TLG values does not appear for readability purposes. 
The central box represents values from the 25 to 75 percentile. The middle line 
represents the median. A line extends from minimum to maximum, excluding 
"outliers" which are displayed as separate points. 
Figure 3: Box-and-whisker distributions plots of ΔSUVmax, ΔSUVpeak, ΔSUVmean, 
ΔMATV and ΔTLG. Optimal cut-off values providing best accuracy in predicting 
response are displayed. 
The central box represents values from the 25 to 75 percentile. The middle line 
represents the median. A line extends from minimum to maximum, excluding 
"outliers" which are displayed as separate points. 
Figure 4: ROC curves related to the prediction of responders, for ΔSUVmax, 
ΔSUVpeak, ΔSUVmean, ΔMATV and ΔTLG, (A) without or (B) with partial volume 
effects correction. 
Figure 5: ROC curves related to the prediction of pCR, for ΔSUVmax, ΔSUVpeak, 











AJCC clinical stage  
IIA 11 (21.5) 
IIB 13 (25.5) 
IIIA  12 (23.5) 
IIIB  14 (27.5) 
IIIC 1 (2) 
Tumor Type  
Invasive ductal, no special type 45 (88) 
Metaplastic 3 (6) 
Lobular 3 (6) 
Grade  
grade-1 4 (8) 
grade-2  28 (55) 
grade-3  17 (33) 
Grade unknown  2 (4) 
Estrogen receptor status**  
Positive 30 (59) 
Negative 21 (41) 
HER2 status†  
Positive 12 (23.5) 
Negative 39 (76.5) 
Triple negative Status  
Triple negative 13 (25.5) 
Not Triple negative 38 (74.5) 
Surgery  
Breast-conserving surgery  25 (49) 
Mastectomy  26 (51) 
Pathological Response  
Responders  27 (53) 
Non-responder  24 (47) 
  AJCC version 7 (16) according to clinical examination and conventional imaging findings. ** Tumors 
were considered positive for ER or for PR if more than 10% of cells showed staining by IHC. † Tumors 
were considered to overexpress c-erbB-2 oncoprotein (HER2-positive) if more than 30% of invasive 
tumor cells showed definite membrane staining resulting in a so-called fishnet appearance. 
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Table 2 – PET parameters values and correlation with response 
Parameter* PET1 p 
† PET2 p 
† Δ(PET1, PET2) (%)
 p † 
SUVmax
 6.8 (2.3, 27.5) 0.8 3.9 (1.4, 30.7) 0.04 -34 (-90, +104) 0.0001 
SUVpeak 4.8 (1.9, 22.0) 0.8 2.9 (1.0, 24.5) 0.07 -39 (-90, +73) 0.0004 
SUVmean 3.7 (1.3, 18.7) 0.7 2.5 (1.0, 17.9) 0.2 -36 (-87, +69) 0.026 
MATV (cm3) 14 (2, 227) 0.1 7 (1, 154) 0.09 -45 (-89, +74) <0.0001 
TLG 51 (9, 668) 0.4 16 (1, 758) 0.05 -59 (-98, +51) <0.0001 
* median (min, max) 
† p value of Mann-Whitney-U test (responders vs. non-responders). Bold indicates significant 
value. 
 







[95% CI]  
(%)  
Specificity 
[95% CI] 
(%) 
Accuracy 
[95% CI] 
(%) 
SUVmax 
PET1 
0.52  
[0.37-0.66] 
>11.6 
30 
[14-50] 
83 
[63-95] 
55 
[38-68] 
PET2 
0.67 
[0.52-0.79] 
<=3.7 
67 
[46-84] 
75 
[53-90] 
71 
[49-87] 
Δ (%) 
0.82 
[0.68-0.91] 
<=-48 
63 
[42-81] 
92 
[73-99] 
77 
[57-90] 
SUVpeak 
PET1 
0.52 
[0.37-0.66] 
>11.7 
22 
[9-42] 
88 
[68-97] 
53 
[34-69] 
PET2 
0.65 
[0.50-0.78] 
<=2.8 
63 
[42-81] 
71 
[49-87] 
67 
[46-85] 
Δ (%) 
0.79 
[0.65-0.89] 
<=-42 
70 
[50-86] 
83 
[63-95] 
76 
[54-91] 
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SUVmean 
PET1 
0.53 
[0.38-0.67] 
<=2.2 
19 
[6-38] 
92 
[73-99] 
53 
[34-69] 
PET2 
0.62 
[0.47-0.75] 
<=2 
59 
[39-78] 
75 
[53-90] 
67 
[46-85] 
Δ (%) 
0.68 
[0.54-0.81] 
<=-30 
74 
[54-89] 
67 
[45-84] 
71 
[49-88] 
MATV 
(cm3) 
PET1 
0.63 
[0.48-0.76] 
>7 
85 
[66-96] 
42 
[22-63] 
65 
[48-79] 
PET2 
0.64 
[0.49-0.77] 
<=11.3 
89 
[71-98] 
42 
[22-63] 
67 
[45-84] 
Δ (%) 
0.92 
[0.82-0.98] 
<=-42 
93 
[76-99] 
88 
[68-97] 
91 
[72-98] 
TLG 
PET1 
0.57 
[0.43-0.71] 
>16 
93 
[76-99] 
29 
[13-51] 
63 
[42-81] 
PET2 
0.66 
[0.51-0.79] 
<=23.3 
78 
[58-91] 
63 
[41-82] 
71 
[49-88] 
Δ (%) 
0.91 
[0.79-0.97] 
<=-56 
96 
[81-100] 
92 
[73-99] 
94 
[79-99] 
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